Rexin-G(TM), The World’s First Tumor-Targeted Gene Therapy Vector, Stymies Metastatic Cancer
SAN MARINO, Calif. and MANILA, Philippines – Nov. 6 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies today announced the publication of clinical data from studies conducted at the University of the Philippines, Asian Hospital and Medical Center, Makati Medical Center, Manila, Philippines and Lutheran Medical Center, New York, USA, revealing the safety and single agent efficacy of Rexin-G(TM) for the treatment of a broad spectrum of chemotherapy-resistant cancers.